Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/8/2018Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Sets Fiscal 2019 Cash Dividend Rate, and Provides Fiscal 2019 Guidance
CINCINNATI, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2018. Business Highlights: Completed consolidation of separately-run businesses into two integrated global business units Streamlined organization to build a stronger, more efficient and sustainable management structure Entered into a strategic collaboration with DiaSorin to sell Helicobacter Pylori tes... 
 Printer Friendly Version
10/17/2018Meridian Bioscience to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on November 8, 2018
CINCINNATI, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report fourth quarter and full year 2018 financial results Thursday, November 8, 2018. Jack Kenny, Chief Executive Officer, Melissa Lueke, Chief Financial Officer, and Eric Rasmussen, Corporate Development, will host a conference call beginning at 9:00 a.m. Eastern Time to discuss the results and answer questions.  During the ... 
 Printer Friendly Version
10/9/2018DiaSorin and Meridian Enter Into a Strategic Collaboration to Sell Helicobacter Pylori Stool Antigen Test in the United States and in the United Kingdom
SALUGGIA, Italy and CINCINNATI, Oct. 09, 2018 (GLOBE NEWSWIRE) -- DiaSorin S.p.A. (FTSE Italy Mid Cap: DIA) and Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that DiaSorin Inc., a subsidiary of DiaSorin S.p.A. and Meridian Bioscience, Inc. have entered into a strategic collaboration to sell DiaSorin’s FDA-cleared Helicobacter pylori stool antigen test to detect H. pylori for use on its automated LIAISON platform under the Meridian brand name worldwide.  ... 
 Printer Friendly Version
9/24/2018Meridian Bioscience Announces Retirement of John A. Kraeutler, Executive Chairman of the Board; Appoints David C. Phillips as Chairman of the Board; and Elects Felicia Williams to the Board of Directors
CINCINNATI, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that John (Jack) A. Kraeutler, Executive Chairman of the Board, will retire effective September 30, 2018. In connection with Mr. Kraeutler’s retirement the Board has appointed David C. Phillips to the position of Chairman, effective September 30, 2018. Additionally, the Board has elected Felicia Williams to the Board of Directors effective September 20, 2018. Ms. Williams has also been appoin... 
 Printer Friendly Version
7/31/2018Meridian Bioscience Reports Third Quarter 2018 Operating Results, Declares Regular Third Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
CINCINNATI, July 31, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today: GENERAL HIGHLIGHTS Reported record fiscal 2018 third quarter and first nine months net revenues of $51.7 million and $160.5 million, respectively, increases of 3% and 6%, respectively, from the same periods of the prior fiscal year;   reported third quarter operating income of $8.7 million (including $2.1 million of costs associated with executive transition and realignment, and litigation... 
 Printer Friendly Version
6/28/2018Meridian Bioscience, Inc. Expects to Report Third Quarter Fiscal Year 2018 Operating Results on Tuesday, July 31, 2018
CINCINNATI, June 28, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading life science company, expects to release its third quarter fiscal 2018 operating results before the NASDAQ market opens on Tuesday, July 31, 2018. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad r... 
 Printer Friendly Version
5/30/2018Meridian Introduces Critical Raw Materials for Nipah Virus Diagnosis, a Key Emerging Disease on the WHO’s Priority List
CINCINNATI, May 30, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the availability of critical antigens and antibodies for Nipah virus immunological assay development in response to the World Health Organization’s (WHO) list of eight priority diseases that could cause severe outbreaks or have epidemic potential. Last week, at least 13 people died as a result of a Nipah virus outbreak in Kerala, India. The Nipah virus outbreak in India's southern state of Kera... 
 Printer Friendly Version
4/26/2018Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance
CINCINNATI, April 26, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: GENERAL HIGHLIGHTS Reported record fiscal 2018 second quarter and first six months net revenues of $56.5 million and $108.7 million, respectively, increases of 4% and 8%, respectively, from the same periods of the prior fiscal year;   reported second quarter operating income of $7.7 million (including $4.9 million of costs associated with executive transition and realignment, and litigation ... 
 Printer Friendly Version
4/4/2018Meridian Bioscience, Inc. Expects to Report Second Quarter Fiscal Year 2018 Operating Results on Thursday, April 26, 2018
CINCINNATI, April 04, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its second quarter fiscal 2018 operating results before the NASDAQ market opens on Thursday, April 26, 2018. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, mark... 
 Printer Friendly Version
3/21/2018Meridian Bioscience Realigns Organizational Structure
New Structure Consists of two Business Units, Diagnostics and Life Science, Supported by a Global Corporate Team Realignment Aimed at Building a Stronger, More Sustainable Organization; Paving the Way for Future Growth Resulting Cost Savings to be Reinvested Back into the Business CINCINNATI, March 21, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the realignment of its business structure aimed at building a stronger, more sustainable organ... 
 Printer Friendly Version
1/25/2018Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance
CINCINNATI, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today: GENERAL HIGHLIGHTS reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the prior fiscal year; reported first quarter operating income of $8.1 million (including $1.5 million of costs associated with transition to a new CEO and litigation costs), a decrease of 20% from the same period of the prior fiscal year; reported first quarter net ... 
 Printer Friendly Version
1/19/2018Meridian Bioscience, Inc. Expects to Report First Quarter Fiscal Year 2018 Operating Results on Thursday, January 25, 2018
CINCINNATI, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its first quarter fiscal 2018 operating results before the NASDAQ market opens on Thursday, January 25, 2018. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com.  About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, mark... 
 Printer Friendly Version